pemtumomab

Home
Ligands
pemtumomab

GtoPdb Ligand ID: 8031

Synonyms: HMFG1 | HuHMFG-1 [2]

Comment: Pemtumomab is a monoclonal antibody directed against a specific antigenic epitope (PDTR sequence in the MUC1 tandem repeat [5]) of the mucin 1 (MUC1) expressed by several types of secretory epithelial-derived cancers [4]. MUC1 is a large, heavily glycosylated mucin. It is expressed on the apical surface of the most secretory epithelial cells [1] and an antigenically distinct form of MUC1 is overexpressed in 90% of adenocarcinomas, including cancers of the ovary, breast, and pancreas. This means that antibodies can be targeted to cancerous cells [3,5], sparing normal tissue. Pemtumomab is labelled with the radioisotope yttrium-90.
This antibody does not appear to have an INN (international non-proprietary name), and no peptide sequences are available.

No information available.

No information available.

Summary of Clinical Use
A single Phase 3 clinical trial (NCT00004115) is registered with ClinicalTrials.gov, although the status of this trial has not been updated for some time. This trial was assessing pemtumomab yttrium-90 in ovarian cancer or primary peritoneal cancer following surgery and chemotherapy. The published results of this trial report that it did not extend survival or time to relapse [6].

Summary of Clinical Use

A single Phase 3 clinical trial (NCT00004115) is registered with ClinicalTrials.gov, although the status of this trial has not been updated for some time. This trial was assessing pemtumomab yttrium-90 in ovarian cancer or primary peritoneal cancer following surgery and chemotherapy. The published results of this trial report that it did not extend survival or time to relapse [6].